Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Prediction of treatment response in patients with newly diagnosed type 2 diabetes : The Skaraborg diabetes register

Pikkemaat, Miriam LU orcid ; Melander, Olle LU orcid ; Hjerpe, Per LU and Bengtsson Boström, Kristina LU (2017) In Journal of Diabetes and its Complications 31(5). p.854-858
Abstract

Aims: Type 2 diabetes is associated with cardiovascular complications. It is largely unknown which patients have poor treatment response and high complication risk; biomarkers are studied for this purpose. The aim of the study was to investigate the association between clinical factors such as HbA1c, level of biomarkers (C-peptide, copeptin) at diagnosis and changes in HbA1c, blood pressure or body mass index (BMI) after five years. Methods: Clinical data and blood samples from 460 newly diagnosed type 2 diabetes patients from the Skaraborg diabetes register (SDR) at diagnosis and after 5. years and were analyzed with linear and logistic regressions. Results: High BMI at diagnosis and smoking were associated with less reduction of HbA1c... (More)

Aims: Type 2 diabetes is associated with cardiovascular complications. It is largely unknown which patients have poor treatment response and high complication risk; biomarkers are studied for this purpose. The aim of the study was to investigate the association between clinical factors such as HbA1c, level of biomarkers (C-peptide, copeptin) at diagnosis and changes in HbA1c, blood pressure or body mass index (BMI) after five years. Methods: Clinical data and blood samples from 460 newly diagnosed type 2 diabetes patients from the Skaraborg diabetes register (SDR) at diagnosis and after 5. years and were analyzed with linear and logistic regressions. Results: High BMI at diagnosis and smoking were associated with less reduction of HbA1c i.e. poorer treatment outcome after 5. years. A high HbA1c at baseline predicted a greater reduction of HbA1c and need for insulin treatment. High systolic blood pressure and BMI at baseline were associated with greater reduction.The biomarkers were not associated with increase of blood pressure, HbA1c, BMI or need for insulin treatment. Conclusions: Smokers and patients with high HbA1c at diagnosis respond poorer to treatment over 5. years. This highlights the importance of advice for non-smoking and weight reduction and more intensive treatment over time.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarkers, Primary health care, Prognosis, Treatment outcome, Type 2 diabetes mellitus
in
Journal of Diabetes and its Complications
volume
31
issue
5
pages
854 - 858
publisher
Elsevier
external identifiers
  • pmid:28319005
  • wos:000401683600013
  • scopus:85015365081
ISSN
1056-8727
DOI
10.1016/j.jdiacomp.2017.02.013
language
English
LU publication?
yes
id
13b18774-d955-4cc3-8484-9636833df7b2
date added to LUP
2017-04-03 10:43:54
date last changed
2025-01-07 10:42:32
@article{13b18774-d955-4cc3-8484-9636833df7b2,
  abstract     = {{<p>Aims: Type 2 diabetes is associated with cardiovascular complications. It is largely unknown which patients have poor treatment response and high complication risk; biomarkers are studied for this purpose. The aim of the study was to investigate the association between clinical factors such as HbA1c, level of biomarkers (C-peptide, copeptin) at diagnosis and changes in HbA1c, blood pressure or body mass index (BMI) after five years. Methods: Clinical data and blood samples from 460 newly diagnosed type 2 diabetes patients from the Skaraborg diabetes register (SDR) at diagnosis and after 5. years and were analyzed with linear and logistic regressions. Results: High BMI at diagnosis and smoking were associated with less reduction of HbA1c i.e. poorer treatment outcome after 5. years. A high HbA1c at baseline predicted a greater reduction of HbA1c and need for insulin treatment. High systolic blood pressure and BMI at baseline were associated with greater reduction.The biomarkers were not associated with increase of blood pressure, HbA1c, BMI or need for insulin treatment. Conclusions: Smokers and patients with high HbA1c at diagnosis respond poorer to treatment over 5. years. This highlights the importance of advice for non-smoking and weight reduction and more intensive treatment over time.</p>}},
  author       = {{Pikkemaat, Miriam and Melander, Olle and Hjerpe, Per and Bengtsson Boström, Kristina}},
  issn         = {{1056-8727}},
  keywords     = {{Biomarkers; Primary health care; Prognosis; Treatment outcome; Type 2 diabetes mellitus}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{5}},
  pages        = {{854--858}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Diabetes and its Complications}},
  title        = {{Prediction of treatment response in patients with newly diagnosed type 2 diabetes : The Skaraborg diabetes register}},
  url          = {{https://lup.lub.lu.se/search/files/31955289/23504994.pdf}},
  doi          = {{10.1016/j.jdiacomp.2017.02.013}},
  volume       = {{31}},
  year         = {{2017}},
}